Rosen Law Firm has filed a class action lawsuit on behalf of investors in Nektar Therapeutics, alleging misleading statements regarding the REZOLVE-AA trial. Investors who purchased Nektar securities between February 26, 2025, and December 15, 2025, may be eligible for compensation.
Related articles
Press ReleaseSeptember 16, 2026
ASSA ABLOY
ASSA ABLOY acquires PACLOCK in the US
September 16, 2026
Press ReleaseSeptember 16, 2026
MySize
MySize Announces $2.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
September 16, 2026
Press ReleaseSeptember 16, 2026
Xpansiv
Xpansiv to Acquire Formbay, Australia's AI-Enabled Renewable Energy Certificate and Compliance Technology Platform
September 16, 2026
← Back to all articles
Generated by Olivia 6